# Intravenous Biosimilar Pharmaceutical Products Celltrion Receives FDA Approval for AVTOZMA® By Kalin Ned | Published 2025-10-09 | Tech Source: Trend Hunter, https://www.trendhunter.com/trends/biosimilar-pharmaceutical-product References: [celltrion](https://www.celltrion.com/en-us/company/media-center/press-release/4191) & [biospectrumasia](https://www.biospectrumasia.com/news/51/26469/koreas-celltrion-receives-us-fda-approval-of-expanded-indication-for-avtozma.html)  Celltrion has introduced a new biosimilar pharmaceutical product, AVTOZMA® (tocilizumab-anoh), in its intravenous form to the United States market. This product is a medically equivalent version of an existing biologic drug known as Actemra®. Celltrion's AVTOZMA® has received regulatory approval for the same set of conditions as Actemra®, which include rheumatoid arthritis, several forms of juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and severe COVID-19. The regulatory clearance was granted following a clinical trial program that compared the new product to the reference medicine. The launch of this biosimilar pharmaceutical product represents an expansion of the Korean company's portfolio by adding a new mechanism of action that targets "[multiple inflammatory pathways](https://www.trendhunter.com/trends/antiinflammatory-agent) and addresses a wider spectrum of diseases and patient populations." Celltrion's AVTOZMA® is accompanied by a support program intended to assist patients with associated costs. Image Credit: Celltrion ## Trend Insights (Trend Hunter) - Score: 6.2/10 - Popularity: 64% | Activity: 71% | Freshness: 50% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America, South America ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Tech](https://www.trendhunter.com/tech) > [Science](https://www.trendhunter.com/science) ## Key Themes ### Why This Trend Is Growing - **Expanding Biosimilar Market:** The introduction of AVTOZMA® highlights the growth potential for biosimilar pharmaceuticals as cost-effective alternatives to original biologics, particularly in markets with high medication expenses. - **Intravenous Treatment Advancements:** The intravenous delivery of biosimilars like AVTOZMA® represents a step forward in enhancing the efficacy and convenience of administering complex biologic treatments to patients with chronic conditions. - **Regulatory Approvals Stimulating Innovation:** The FDA approval of AVTOZMA® signifies a trend of accelerating regulatory clearances that invite pharmaceutical companies to innovate and diversify their biosimilar offerings. ### Industries Being Reshaped - **Pharmaceuticals:** The approval of AVTOZMA® by Celltrion underscores significant disruptive chances within the pharmaceutical sector to produce and market biosimilars that challenge existing biologics. - **Healthcare Services:** The expansion of intravenous biosimilars introduces new prospects for healthcare services to integrate these treatments into routine care, potentially improving accessibility and outcomes for patients. - **Biotechnology:** As biosimilar products like AVTOZMA® gain market traction, the biotechnology industry stands to benefit from advancements in production technologies and capabilities for biologic-like therapeutics. ## Related on Trend Hunter - [Eu-Wide Biosimilar Drug Expansions](https://www.trendhunter.com/trends/biosimilar-drug.md) - [Lymphoma-Focused Bispecific Antibody Regimens](https://www.trendhunter.com/trends/antibody-regimen.md) - [Innovative Osteoarthritis Treatments](https://www.trendhunter.com/trends/osteoarthritis-treatment.md) - [Injectable Health Medicines](https://www.trendhunter.com/trends/avenacy-1.md) - [Multi-Use Injectable Medications](https://www.trendhunter.com/trends/avenacy.md) - [Preventative COVID-19 Antibody Drugs](https://www.trendhunter.com/trends/covid19-antibody-drug.md) - [Medical Device Expansions](https://www.trendhunter.com/trends/teleflex-incorporated.md) - [Efficiency-Promoting Pharmaceutical Tools](https://www.trendhunter.com/trends/talktrx.md) - [High-Quality Generic Pharmaceuticals](https://www.trendhunter.com/trends/camber-pharmaceuticals.md)